Fixed-Ratio Spirometry Underdiagnoses COPD in African Americans
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 2, 2023 -- The fixed-ratio spirometric criteria for chronic obstructive pulmonary disorder (COPD) underdiagnoses potential COPD in African American patients, according to a study recently published in the Journal of General Internal Medicine.
Elizabeth A. Regan, M.D., Ph.D., from National Jewish Health in Denver, and colleagues compared COPD diagnosis by fixed ratio with findings and outcomes by race. The analysis included current or former smokers with ≥10-pack-year smoking history.
The researchers found that using the fixed ratio, 70 percent of African Americans were classified as non-COPD versus 49 percent of non-Hispanic White patients. Twelve-year mortality was similar for African American smokers despite being younger (55 versus 62 years), more often currently smoking (80 versus 39 percent), and having fewer pack-years. For forced expiratory volume in the first one second (FEV1) and forced vital capacity (FVC) raw spirometry values, density distribution plots showed disproportionate reductions in FVC relative to FEV1 in African Americans that systematically led to higher ratios. African Americans with GOLD 0 stage had greater symptoms; worse diffusing capacity for carbon monoxide, spirometry, and BODE scores; and greater deprivation than White participants in a matched analysis.
“Broader diagnostic criteria for COPD are needed to identify the disease across all populations,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.